LOS ANGELES, CA / ACCESSWIRE / February 24, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Opera Limited ("Opera" or "the Company") (NASDAQ:OPRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 (the "IPO" or "Offering"); and/or between July 27, 2018 and January 15, 2020, inclusive (the "Class Period") are encouraged to contact the firm before March 24, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Opera seriously overstated its market opportunity and sustainable growth for its browser applications. The Company funded and controlled loan services that engaged in predatory lending practices. These practices were likely to impact the Company's ability to make its apps available on the Google Play Store. Based on these facts, the Company's public statements and offering documents were false and materially misleading throughout the class period. When the market learned the truth about Opera, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 577509

This Florida-based family-owned business is a fully licensed residential and commercial roofing contractor, as well as a Mold, Water, and Fire Restoration Company.

PALM BEACH, FL / ACCESSWIRE / February 23, 2020 / Rafael is a graduate of Northwood University, Florida, in 2011. He has a bachelor's degree in Business Administration. After graduating, he went working in an Insurance Adjusting field. He had a dream of building his own company. This dream turned into reality when he founded this business, American One Roofing Construction & Restoration Inc.

His everyday responsibilities consist of managing the sales team, overseeing all company financials, strategic planning, and building and maintaining vendor and customer relationships. His main goal is to assure the satisfaction of the customers by adding value and giving exceptional services.

American One Roofing Construction and Restoration Inc. aims to serve the community, both the commercial and residential sectors, with the most qualified and uncompromising workmanship and service. They want to provide the public with the services that match their preferences in building and owning properties.

This company possesses the following core values: profit, personal, customer loyalty, and customer satisfaction. Profit stands for providing exceptional services to the public to be a profit-producing company. For personal, this aims to be organized, clean, and prepared to be a more presentable company for the community. Customer Loyalty means the company has already built a credible relationship with the customers. A referral is the best compliment that they could ever receive. Customer satisfaction is the best price for the workers. Their happiness completes the work for the assurance that they are served well.

They are willing to provide the needs of the customers. They take full responsibility for their words that they give to them. American One Roofing Construction and Restoration Inc. provide exceptional services during the time of need. May it be a full roof replacement or insurance-related loss. They have combined 20 years of experience in the roofing and remediation business. This company is ready to guide you through any problems that you may encounter along the way.

The target audience of this residential and commercial roofing company is the homeowners with a need for roof replacement or those who suffered from an insurance-related loss. Their ability to manage small roof leaks, full roof replacement, or even a huge mold project is very evident. They have the expertise, equipment, and trained technicians to handle any work.

American One Roofing Construction and Restoration Inc. also have the experience and background to assure the customer's insurance claim is paid correctly if they decide to go that route. This company aims to get proof of being a market leader in roofing and restoration. They are to provide easier and stress-free construction or restoration portion. This company values the painless process of house renovation for the homeowners. It is perfect if you have a family to take care of and a full-time job wherein you do not have much time to make the repairs on your own. Feel free to contact them at 1(561)701-8996 or email them at rpaiva@americanoneroofing.com for inquiries and quotations. They are more than happy to give you quality and no-hassle service.

SOURCE: American One Roofing Construction & Restoration Inc

ReleaseID: 577497

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD

Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced expanded results from the previously reported interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD). The data were presented today in the oral latebreaker session at the 2020 Transplantation & Cellular Therapy (TCT) Meetings.

As announced in November 2019, KD025 met the primary endpoint of Overall Response Rate (ORR) at the study's planned interim analysis, two months after completion of enrollment. KD025 showed statistically significant and clinically meaningful ORRs of 64% with KD025 200 mg once daily (95% Confidence Interval (CI): 51%, 75%; p<0.0001) and 67% with KD025 200 mg twice daily (95% CI: 54%, 78%; p<0.0001). In the expanded KD025-213 dataset presented today, ORRs were consistent with the previously reported interim analysis across key subgroups, including in patients with four or more organs affected by cGVHD (n=69; 64%), patients who had prior treatment with ibrutinib (n=45; 62%) and patients who had prior treatment with ruxolitinib (n=37; 62%). Three patients achieved a Complete Response. Responses were observed in all affected organ systems, including in organs with fibrotic disease. KD025 has been well tolerated: adverse events were consistent overall with those expected to be observed in cGVHD patients receiving corticosteroids, and no apparent increased risk of infection was observed. Additional secondary endpoints, including duration of response, corticosteroid dose reductions, Failure-Free Survival, Overall Survival and Lee Symptom Scale reductions continue to mature and will be available later in 2020.

"KD025 has been well tolerated and has already demonstrated high response rates in patients with severe and complex cGVHD after a median of five months of follow-up," said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School; Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute and a KD025-213 study investigator and Steering Committee member.

"We are extremely pleased with the interim outcomes of this pivotal trial of KD025 in cGVHD, which track closely our findings from our earlier Phase 2 study. KD025 achieved robust response rates across all subgroups of this difficult-to-treat patient population, who had a median of four prior lines of therapy, and 73% of whom had no response to their last line of treatment," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We plan to meet with the FDA for a pre-NDA meeting in March 2020 and to announce topline results from the primary analysis of this trial in Q2 2020."

At the TCT Meetings, Kadmon also presented long-term follow-up data from KD025-208, its ongoing Phase 2 study of KD025 in cGVHD (Abstract #15205). These data were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in December 2019.

About the ROCKstar (KD025-213) Trial

KD025-213 is an ongoing open-label trial of KD025 in adults and adolescents with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive KD025 200 mg once daily or KD025 200 mg twice daily, enrolling 66 patients per arm. Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%.

While the ORR endpoint was met at the interim analysis, which was conducted as scheduled two months after completion of enrollment, topline data from the primary analysis of the KD025-213 study, six months after completion of enrollment, will be reported in Q2 2020. Full data from the primary analysis will be submitted for presentation at an upcoming scientific meeting.

About KD025

KD025 is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates immune response as well as fibrotic pathways. In addition to cGVHD, KD025 is being studied in an ongoing Phase 2 clinical trial in adults with diffuse cutaneous systemic sclerosis (KD025-209). KD025 was granted Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with cGVHD who have received at least two prior lines of systemic therapy.

About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD, and approximately 5,000 new patients are diagnosed with cGVHD per year.

About Kadmon

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe, China, Japan and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel (xx) the potential benefits from any of our product candidates being granted orphan drug or breakthrough designation; (xxi) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxii) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri, Investor Relations
646.490.2989
ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

ReleaseID: 577466

LOS ANGELES, CA / ACCESSWIRE / February 23, 2020 / Compare-autoinsurance.org (http://compare-autoinsurance.org/) is a top auto insurance brokerage website, providing car insurance quotes online from trustworthy agencies all over the United States. This website offers car insurance info about different coverage types, available discounts, and money-saving tips.

Auto insurance covers much more than accidents and drivers should be aware of that. There are times when certain acts of nature may occur such as a tornado or a falling tree that may cause damage to an automobile and it would cost too much money out of pocket to repair or replace these things. The insurance will sometimes ask for a deductible depending on the type of accident that has occurred, but the cost is minimal compared to what it would cost to fix an automobile on your own. Find out why car insurance is important for new cars and have a look at our website if you want to get online auto insurance quotes.

These are the following reasons why drivers should get car insurance:

You are protecting your automobile, one of the largest investments anyone can make. Besides home, a car is the most valuable thing you can own. And if you just bought the car, make sure it is well protected.

 You are able to pay for medical bills if an accident occurs. Just paying for a car can surely drain your pockets. And if you have to pay for medical bills after an accident, you will surely get some financial difficulties.

 You don't have to feel the biggest part of an accident-related lawsuit. Do not forget that insurance companies also work with their specialized lawyers.

 Protects assets that you've worked hard for from being lost due to a lawsuit. If you do not have insurance or sufficient insurance, you risk losing your assets that will be sold to reimburse the victims.

 Protects you from those motorists that may not have insurance of their own. Get Uninsured or Underinsured Motorist Insurance.

 Not only pays for accidents and weather-related incidents but it also pays for vandalism and theft. This is why you should get comprehensive car insurance.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org/.

CONTACT:

Company Name: Internet Marketing Company
Person for contact Name: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org

SOURCE: Internet Marketing Company

ReleaseID: 577481

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Beyond Meat, Inc. (NASDAQ: BYND)
Class Period: May 2, 2019 to January 27, 2020
Lead Plaintiff Deadline: March 30, 2020

According to the complaint, Beyond Meat, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Beyond Meat’s termination of its supply agreement with Don Lee constituted a breach of that agreement, thus exposing the Company to foreseeable legal liability and reputational harm; (ii) Beyond Meat and certain of its employees had doctored and omitted material information from a food safety consultant’s report, which the Company represented as accurate to Don Lee; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BYND: http://www.kleinstocklaw.com/pslra-1/beyond-meat-inc-loss-submission-form?id=5507&from=1

Westpac Banking Corporation (NYSE: WBK)
Class Period: November 11, 2015 to November 19, 2019
Lead Plaintiff Deadline: March 30, 2020

The WBK lawsuit alleges that throughout the class period, Westpac Banking Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to Australian law, the Company failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre ("AUSTRAC"); (2) the Company did not appropriately monitor and assess the ongoing money laundering and terrorism financing risks associated with movement of money into and out of Australia; (3) the Westpac did not pass on requisite information about the source of funds to other banks in the transfer chain; (4) despite being aware of the heightened risks, the Company did not carry out appropriate due diligence on transactions in South East Asia and the Philippines that had known financial indicators relating to child exploitation risks; (5) the Company's Anti-Money Laundering and Counter-Terrorism Financing Policy Program was inadequate to identify, mitigate and manage money laundering and terrorism financing risks; and (6) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in WBK: http://www.kleinstocklaw.com/pslra-1/westpac-banking-corporation-loss-submission-form?id=5507&from=1

HP Inc. (NYSE: HPQ)
Class Period: February 23, 2017 to October 3, 2019
Lead Plaintiff Deadline: April 20, 2020

According to the filed complaint, defendants knew that HP's "four-box" model for measuring its supplies business was severely deficient and not a strong predictor of supplies demand and outcomes because HP lacked telemetry data from its commercial printers and had to use unreliable and stagnant market share data to develop assumptions for the four-box model. The complaint further alleges that defendants knew the lack of telemetry data for commercial printing was a critical shortcoming of the four-box model because HP possessed telemetry data on its personal printing side and knew it was a necessary element for an accurate understanding of the supplies channel. As a result, the supplies inventory in the Company’s channel exceeded demand by at least $100 million and HP’s supplies revenue growth was grossly inflated.

Learn about your recoverable losses in HPQ: http://www.kleinstocklaw.com/pslra-1/hp-inc-loss-submission-form?id=5507&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 577490

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

PTLA Shareholders Click Here: https://www.zlk.com/pslra-1/portola-pharmaceuticals-inc-loss-form?prid=5508&wire=1
QD Shareholders Click Here: https://www.zlk.com/pslra-1/qudian-inc-loss-form?prid=5508&wire=1
LK Shareholders Click Here: https://www.zlk.com/pslra-1/luckin-coffee-inc-loss-form?prid=5508&wire=1

* ADDITIONAL INFORMATION BELOW *

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

PTLA Lawsuit on behalf of: investors who purchased May 8, 2019 – January 9, 2020
Lead Plaintiff Deadline : March 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/portola-pharmaceuticals-inc-loss-form?prid=5508&wire=1

According to the filed complaint, during the class period, Portola Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Portola's internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Qudian Inc. (NYSE:QD)

QD Lawsuit on behalf of: investors who purchased December 13, 2018 – January 15, 2020
Lead Plaintiff Deadline : March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/qudian-inc-loss-form?prid=5508&wire=1

According to the filed complaint, during the class period, Qudian Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Luckin Coffee Inc. (NASDAQ:LK)

LK Lawsuit on behalf of: investors who purchased November 13, 2019 – January 31, 2020
Lead Plaintiff Deadline : April 13, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/luckin-coffee-inc-loss-form?prid=5508&wire=1

According to the filed complaint, during the class period, Luckin Coffee Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) certain of Luckin's financial performance metrics, including per-store per-day sales, net selling price per item, advertising expenses, and revenue contribution from "other products" were inflated; (ii) Luckin's financial results thus overstated the Company's financial health and were consequently unreliable; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 577491

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Sasol Limited (NYSE: SSL)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sasol-limited-loss-submission-form?prid=5509&wire=1
Lead Plaintiff Deadline: April 6, 2020
Class Period: March 10, 2015 to January 13, 2020

Allegations against SSL include that: (i) Sasol had conducted insufficient due diligence into, and failed to account for multiple issues with, the Lake Charles Chemicals Project ("LCCP"), as well as the true cost of the project; (ii) construction and operation of the LCCP was consequently plagued by control weaknesses, delays, rising costs, and technical issues; (iii) these issues were exacerbated by Sasol's top-level management, who engaged in improper and unethical behavior with respect to financial reporting for the LCCP and the project's oversight; (iv) all the foregoing was reasonably likely to render the LCCP significantly more expensive than disclosed and negatively impact the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Forescout Technologies, Inc. (NASDAQ: FSCT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/forescout-technologies-inc-loss-submission-form?prid=5509&wire=1
Lead Plaintiff Deadline: March 2, 2020
Class Period: February 7, 2019 to October 9, 2019

Allegations against FSCT include that: (i) Forescout was experiencing significant volatility with respect to large deals and issues related to the timing and execution of deals in the Company's pipeline, especially in Europe, the Middle East, and Africa; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Geron Corporation (NASDAQ: GERN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5509&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 577492